Saturday 17 October 2026 Export IRIX’s income statement to Excel — free account

IRIDEX Corporation

IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.81 0.01 −1.22%

Follow IRIX

Alert me

Market cap: $14.5M
P/E: 0.0×
Fwd P/E: −21.8×
Dividend yield: —
F-score: 4/9
Altman Z: −1.95
Beneish M: −2.75
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.59

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	6	6	7	4	1	—	1	5	—	1	3	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 38.34%

Capital & Financial Ratios $m

Market Cap 14.49

Revenue 51.57

Net Income (3.55)

Free Cash Flow (2.00)

Net Debt (0.88)

Current Ratio 1.82

Debt/Equity 1.04

P/E ratio 0.00

Fwd P/E (21.80)

P/S ratio 0.28

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 53.85%

Next Y EPS Growth 100.00%

Next Y revenue growth (0.29%)

Next 5Y EPS Growth 30.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.55%

10-year low 10-year high

EV/Sales against its own 10 years 3.46%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7	2	6	5
Receivables	10	8	10	7
Inventory	10	11	8	10
Other	—	—	—	—
	27	24	25	24

	2023	2024	2025	Q'26
Payables	4	7	5	7
ST’ Debt	—	2	—	—
Other	1	2	2	2
	13	17	13	13

Compound Annual Growth %

	10y	5y	3y
Sales	2.35%	7.70%	(2.58%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(17.50%)	(22.29%)	(34.14%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	12	13	—	—	—
’25	12	14	12	15	53
’24	12	13	12	13	49
’23	14	13	13	12	52
’22	13	14	15	15	57
’21	12	13	13	15	54
’20	9	6	9	12	36

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	0	(1)	1	(2)
’24	(2)	(1)	(3)	(1)	(7)
’23	(3)	(1)	(2)	(1)	(7)
’22	(3)	(3)	(2)	(2)	(10)
’21	12	(1)	(1)	(2)	8
’20	(1)	(2)	0	0	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	0	(1)	0	(2)
’24	(2)	(1)	(3)	(1)	(7)
’23	(3)	(1)	(2)	(1)	(7)
’22	(3)	(3)	(2)	(2)	(10)
’21	12	(1)	(1)	(2)	8
’20	(2)	(2)	0	0	(3)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	(0.07)	—	—	—
’25	(0.10)	(0.06)	(0.09)	(0.01)	(0.26)
’24	(0.21)	(0.16)	(0.12)	(0.05)	(0.54)
’23	(0.13)	(0.17)	(0.11)	(0.18)	(0.59)
’22	(0.15)	(0.14)	(0.11)	(0.07)	(0.47)
’21	(0.14)	0.09	(0.14)	(0.15)	(0.34)
’20	(0.12)	(0.20)	(0.12)	(0.01)	(0.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.50	7.43	3.72	1.50	1.22	2.13	1.96	1.31	1.27	0.78	Analyst estimates 2026–2028 Powerpack
	High	16.64	16.37	9.48	5.69	4.24	9.71	6.48	3.48	3.65	1.87
People
People	Employees	121	116	114	94	89	119	130	111	93	93
	Revenue/emp, $m	0.38	0.36	0.37	0.46	0.41	0.45	0.44	0.47	0.52	0.57
Income, $m
Income, $m	Revenue	46	42	43	43	36	54	57	52	49	53
	Gross margin, %	45.15	37.27	41.01	41.29	42.80	42.36	44.53	42.04	40.07	36.50
	EBT	(3)	(13)	(13)	(9)	(6)	(5)	(7)	(9)	(9)	(4)
	EBT margin, %	(5.75)	(31.24)	(29.99)	(20.17)	(17.34)	(9.62)	(13.13)	(18.28)	(18.17)	(8.32)
	Net income	(12)	(13)	(13)	(9)	(6)	(5)	(8)	(10)	(9)	(4)
	Depreciation	1	1	1	1	1	1	0	1	2	2
Per share, $
Per share, $	Revenue	4.54	3.60	3.49	3.17	2.63	3.50	3.57	3.22	2.96	3.11
	Earnings	(1.15)	(1.11)	(1.05)	(0.64)	(0.46)	(0.34)	(0.47)	(0.59)	(0.54)	(0.26)
	Cash flow	(0.01)	(0.31)	(0.82)	(0.58)	(0.23)	0.53	(0.60)	(0.42)	(0.44)	(0.12)
	Capex	(0.10)	(0.03)	(0.04)	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	0.00	(0.01)
	Free cash flow	(0.12)	(0.34)	(0.86)	(0.59)	(0.24)	0.52	(0.62)	(0.42)	(0.44)	(0.13)
	Book value	3.85	2.64	2.46	1.66	1.25	1.51	1.08	0.59	0.13	0.29
	Shares, m	10	12	12	14	14	15	16	16	16	17
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	3.05	2.21	1.35	0.70	0.96	1.75	0.58	0.89	0.57	0.37
	P/B	3.60	3.01	1.91	1.35	2.00	4.04	1.91	4.86	13.17	0.00
	EV/Sales	2.54	1.69	0.85	0.49	0.70	1.35	0.36	0.81	0.57	0.36
	EV/FCF	(97.14)	(16.97)	(3.45)	(2.63)	(7.69)	9.12	(2.11)	(6.15)	(3.83)	(8.30)
Cash, $m
Cash, $m	Operating cash flow	0	(4)	(10)	(8)	(3)	8	(10)	(7)	(7)	(2)
	Capex	(1)	0	0	0	0	0	0	0	0	0
	Free cash flow	(1)	(4)	(10)	(8)	(3)	8	(10)	(7)	(7)	(2)
Balance, $m
Balance, $m	Working capital	38	29	29	21	17	30	23	14	7	12
	Total debt	—	—	—	3	2	3	2	—	3	4
	Net debt	(24)	(22)	(21)	(9)	(9)	(21)	(12)	(7)	0	(2)
	Shareholders’ equity	39	31	30	23	17	23	17	10	2	5
Returns, %
Returns, %	ROA	(26.04)	(28.66)	(30.76)	(23.05)	(20.16)	(13.63)	(16.59)	(24.95)	(28.03)	(15.22)
	ROIC	(10.40)	(91.38)	(91.74)	(42.30)	(49.95)	(223.88)	(92.83)	(251.38)	(211.96)	(61.12)
	ROE	(32.16)	(36.93)	(42.37)	(33.47)	(31.59)	(25.70)	(37.24)	(71.54)	(153.37)	(870.85)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BDMD Baird Medical Investment Holdings Limited	$19.2M	— (loss-making)	—	—	n/m	−598.12% (below 0%: shrinking)	—	—	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)	Compare
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
Median of peers	$14.9M	—	—	+11.94%	—	+29.16%	61.50%	(126.60%)

All 149 Medical Devices stocks →

IRIDEX Corporation (IRIX) key facts

Concern: IRIDEX Corporation reported a net loss of $4.4 million, or a loss of $0.26 per share, for fiscal 2025.
Strength: IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024.
IRIDEX Corporation (IRIX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IRIX traded at $0.81, a market capitalization of $14.5 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.3× sales.
Return on equity was −870.9% and debt-to-equity 1.04.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.95 (distress zone) for fiscal 2025.